

Dated: 12th February, 2019

To
The Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P.J. Towers,
Dalal Street, Mumbai-400001

Company Code No: 532771

To
The National Stock Exchange of India Limited
"Exchange Plaza",
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai-400 051

NSE Symbol: JHS

Dear Sir/ Madam,

Subject: Submission of Unaudited Standalone and Consolidated IND AS Financial Results for the quarter/nine months ended 31st December, 2018 pursuant to Compliance of Regulation 33 of the of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Please find enclosed herewith the following documents in compliance with the Regulation 33 of the of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015:

1. Unaudited Standalone and Consolidated IND AS Financial results along with Limited Review Report thereon for the quarter/nine months ended 31st December, 2018.

This is for your kind information and record.

Thanking you,

Yours sincerely,
For **JHS SVENDGAARD LABORATORIES LIMITED**



Sanjeev K. Singh
Company Secretary & Compliance Officer
M.No. F6295

**Encl.: 1. Unaudited Standalone and Consolidated IND AS Financial results
2. Limited Review Report**

Limited Review Report

To the Board of Directors of JHS Svendgaard Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JHS Svendgaard Laboratories Limited ("the Company") for the quarter ended 31 December 2018 and year to date results for the period from 01 April 2018 to 31 December 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, other accounting principles generally accepted in India and SEBI Circular dated 5 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S. N. Dhawan & Co LLP
Chartered Accountants
Firm Registration No.: 000050N/N500045


S. K. Khattar
Partner
M. No. 084993



Place: New Delhi
Date: 12 February 2019

JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Khari (Kala-Amb), Tehsil Nahar, Distt. Sirmour, Himachal Pradesh - 173030, INDIA

CIN-L24230HP2004PLC027558

(Rs. In Lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2018

S.No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months	Nine Months	Year Ended 31st
		31st Dec 2018	30th Sep 2018	31st Dec 2017	Ended 31st Dec 2018	Ended 31st Dec 2017	March 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations (Refer note no. 5)	3,792.01	2,894.85	4,303.16	8,607.80	10,354.10	14,073.16
	(b) Other income (Refer note no. 7)	(63.55)	236.82	108.12	288.68	279.78	494.78
	Total income	3,728.46	3,131.67	4,411.28	8,896.48	10,633.88	14,567.94
2	Expenses						
	(a) Cost of materials consumed	2,602.00	2,016.92	2,666.03	5,750.26	6,168.91	8,214.17
	(b) Purchase of stock-in-trade	-	-	-	-	-	76.47
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(37.98)	123.43	42.94	145.38	510.66	762.68
	(d) Excise duty (Refer note no. 5)	-	-	-	-	235.03	235.03
	(e) Employee benefits expenses	229.10	206.56	309.41	645.09	646.21	940.83
	(f) Finance costs	26.42	26.73	16.29	65.64	51.25	73.65
	(g) Depreciation and amortisation expenses	176.33	174.65	173.50	524.19	509.64	680.64
	(h) Other expenses	467.65	518.86	699.38	1,369.70	1,652.57	2,202.02
	Total expenses	3,463.52	3,067.15	3,907.55	8,500.26	9,774.27	13,185.49
3	Profit before exceptional items and tax (1-2)	264.94	64.52	503.73	396.22	2,727.21	1,382.45
4	Exceptional items	-	-	-	-	2,727.21	2,727.21
5	Profit before tax (3+4)	264.94	64.52	503.73	396.22	3,586.82	4,109.66
6	Tax expense	50.16	13.90	11.60	70.05	13.34	198.23
	Current Tax	50.16	13.90	11.60	70.05	13.34	198.23
	Deferred Tax (including MAT credit entitlement)	57.42	18.33	169.77	94.36	1,134.16	1,096.54
	Adjustment of tax	-	-	-	-	-	9.85
7	Net Profit for the period (5-6)	157.36	32.29	322.36	231.81	2,439.32	2,805.04
8	Other comprehensive income						
(a)	-Items that will not be reclassified to profit or loss	0.56	0.56	1.36	1.67	4.06	2.22
	-Income tax relating to items that will not be reclassified to profit or loss	(0.14)	(0.16)	(0.41)	(0.46)	(1.25)	(0.65)
(b)	-Items that will be reclassified to profit or loss	-	-	-	-	-	-
	-Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive income (7+8)	157.78	32.69	323.31	233.02	2,442.13	2,806.61
10	Paid-up equity share capital (Face value per share Rs. 10/-)	6,090.05	6,090.05	6,090.05	6,090.05	6,090.05	6,090.05
11	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	-	-	-	-	-	11,573.56
12	Earnings per equity share						
	(a) Basic (Rs.)	0.26	0.05	0.58	0.38	4.43	4.96
	(b) Diluted (Rs.)	0.26	0.05	0.53	0.38	4.00	4.60



Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in the respective meetings held on 12th February 2019. The same have been reviewed by the Statutory Auditors of the Company as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 Paid up equity share capital includes 1,63,60,000 equity shares allotted pursuant to conversion of share warrants. These shares are under process for listing.
- 3 In line with the provisions of Ind AS 108 - Operating Segments and on the basis the review of operations being done by the senior management, the operations of the Company fall under Manufacturing of Oral Care products, which is considered to be the only reportable segment by the management.
- 4 Ind AS 115 Revenue from contracts with customers has been made applicable w.e.f 1st April 2018. The company has assessed that there is no significant impact of Ind AS 115 on these financial results.
- 5 Revenue from operations for the current quarter and nine months are not comparable with previous periods since sales for the current quarter and nine months are net of Goods and Services Tax (GST), whereas excise duty formed part of the other expenses in the corresponding nine months.

(Rs. In Lakhs)

Particulars	Quarter Ended 31st Dec 2018	Quarter Ended 30th Sep 2018	Quarter Ended 31st Dec 2017	Nine Months Ended 31st Dec 2018	Nine Months Ended 31st Dec 2017	Year Ended 31st March 2018
Sales/Revenue from operations (as reported)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	3,792.01	2,894.85	4,303.16	8,607.80	10,354.10	14,073.16
Less: Excise duty on sales	-	-	-	-	-	235.03
Sales/Income from operations (net of excise duty)	3,792.01	2,894.85	4,303.16	8,607.80	10,119.07	13,838.13

- 6 Deferred tax includes MAT credit entitlement of Rs 50.16 lakhs for the current quarter and Rs 70.05 lakhs for nine months period ended 31st December 2018.
- 7 There has been a major movement in exchange fluctuation in the current quarter as compared to the already recognised gain till september quarter as a result of which the other income figure is negative in the current quarter.
- 8 The Statutory Auditors had qualified their audit report on the financial statements of the Company for the year ended 31st March 2018 in respect of revenue recognition. However this qualification has no impact on current reportable period.
- 9 Figures for the previous quarters/years have been regrouped and reclassified to conform with current quarter/year presentation, where ever applicable.

Place : New Delhi

Date : 12 February, 2019



By Order of the Board
Nikhil Nanda
Managing Director
DIN : 00051501



Limited Review Report

To the Board of Directors of JHS Svendgaard Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of **JHS Svendgaard Laboratories Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 31 December 2018 and year to date results for the period from 01 April 2018 to 31 December 2018 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, other accounting principles generally accepted in India and SEBI Circular dated 5 July 2016 is the responsibility of the Holding Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and upon consideration of the review reports of other auditors, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



We did not review the financial results of three subsidiaries, included in the Statement, whose financial results reflect total revenues of ₹ 152.91 lakhs and ₹ 318.53 lakhs for the quarter ended 31 December 2018 and year to date results for the period from 01 April 2018 to 31 December 2018 respectively, total loss after tax of ₹ 99.08 lakhs and ₹ 329.31 lakhs for the quarter ended 31 December 2018 and year to date results for the period from 01 April 2018 to 31 December 2018 respectively, other comprehensive income of ₹ Nil and ₹ Nil for the quarter ended 31 December 2018 and year to date results for the period from 01 April 2018 to 31 December 2018 respectively as considered in the unaudited financial results. These financial result have been reviewed by other auditors whose review reports have been furnished to us and our report in respect thereof is based solely on the review reports including financial result of such other auditors. Our opinion is not qualified in respect of this matter.

For S. N. Dhawan & Co LLP
Chartered Accountants
Firm Registration No. 000050N/N500045


S. K. Khattar
Partner
M. No. 084993



Place: New Delhi
Date: 12 February 2019

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2018

S.No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months	Nine Months	Year Ended 31st
		31st Dec 2018	30th Sep 2018	31st Dec 2017	31st Dec 2018	31st Dec 2017	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations (Refer note no. 11)	3,943.10	2,978.22	4,381.37	8,924.51	10,484.31	14,264.19
	(b) Other income (Refer note no. 12)	(38.36)	199.32	108.17	290.50	279.85	498.06
	Total Income	3,904.74	3,177.54	4,489.54	9,215.01	10,764.16	14,762.25
2	Expenses						
	(a) Cost of materials consumed	2,633.21	2,052.33	2,666.03	5,839.43	6,168.91	8,214.17
	(b) Purchase of stock-in-trade	-	-	-	-	-	116.27
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	23.55	112.69	48.03	198.83	500.85	676.99
	(d) Excise Duty (Refer note no. 11)	-	-	-	-	235.03	235.03
	(e) Employee benefits expense	337.34	306.77	406.39	980.48	831.32	1,210.04
	(f) Finance Costs	27.58	26.99	18.31	67.44	53.84	73.75
	(g) Depreciation and amortisation expense	183.42	181.54	178.18	545.00	515.78	681.32
	(h) Other expenses	573.33	603.78	759.63	1,632.93	1,762.07	2,436.58
	Total expenses	3,778.43	3,284.10	4,076.57	9,264.11	10,067.80	13,644.15
3	Profit / (Loss) before exceptional items and tax (1-2)	126.31	(106.56)	412.97	(49.10)	696.36	1,118.11
4	Exceptional items	-	-	0.10	-	2,724.25	2,724.25
5	Profit / (Loss) before tax (3+4)	126.31	(106.56)	413.07	(49.10)	3,420.61	3,842.36
6	Tax expense/(income)						
	Current Tax	50.16	13.90	11.60	70.05	13.34	198.23
	Deferred Tax (including MAT credit entitlement)	17.88	(18.81)	153.55	(21.65)	1,082.40	1,028.83
	Tax for earlier years	-	-	-	-	-	9.85
7	Net Profit / (Loss) for the period (5-6)	58.27	(101.65)	247.92	(97.50)	2,324.87	2,605.45
8	Other comprehensive income						
	(a) -Items that will not be reclassified to profit or loss	0.56	0.56	1.35	1.67	6.09	2.22
	-Income tax relating to items that will not be reclassified to profit or loss	(0.14)	(0.16)	(0.32)	(0.46)	(1.78)	(0.65)
	(b) -Items that will be reclassified to profit or loss	-	-	-	-	-	-
	-Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total comprehensive income (7+8)	58.69	(101.25)	248.95	(96.29)	2,329.18	2,607.02
	Net profit attributable to:						
	Owners of the Company	84.17	(92.94)	251.52	(54.88)	2,330.41	2,614.94
	Non-controlling interest	(25.90)	(8.71)	(3.60)	(42.62)	(5.54)	(9.49)
	Other Comprehensive Income attributable to:						
	Owners of the Company	0.42	0.39	1.03	1.21	4.24	1.58
	Non-controlling interest	-	-	-	-	0.07	-
	Total Comprehensive Income attributable to:						
	Owners of the Company	84.59	(92.55)	254.37	(53.68)	2,334.65	2,616.51
	Non-controlling interest	(25.90)	(8.70)	(5.42)	(42.61)	(5.47)	(9.49)
10	Paid-up equity share capital (Face value per share Rs. 10/-)	6,090.05	6,090.05	6,090.05	6,090.05	6,090.05	6,090.05
11	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						11,336.47
12	Earnings per equity share						
	(a) Basic (Rs.)	0.10	(0.17)	0.45	(0.16)	4.22	4.61
	(b) Diluted (Rs.)	0.10	(0.17)	0.41	(0.16)	3.81	4.27



Notes:
 1(a) Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has opted to publish only the consolidated financial results. Investors can view the standalone results of the Company on the Company's web site www.svendgaard.com or on the website of BSE (www.bseindia.com) or NSE (www.nseindia.com).

1(b) Information of standalone financial results is as under:

Particulars	Quarter Ended		Quarter Ended		Nine Months		Nine Months		Year Ended 31st March 2018
	31st Dec 2018	30th Sep 2018	31st Dec 2017	31st Dec 2018	Ended 31st Dec 2018	Ended 31st Dec 2017	Ended 31st Dec 2017		
Revenue from operation	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Profit before tax	3,792.01	2,894.85	4,303.16	8,607.80	10,354.10	14,073.16	4,109.66	2,805.04	
Net Profit after tax for the period	264.94	64.52	503.73	396.22	3,586.82	4,109.66	2,805.04	1,57	
Other Comprehensive Income (Net)	157.36	32.29	322.36	231.81	2,439.32	2,805.04	1,57	2,806.61	
Total Comprehensive Income	0.42	0.40	0.95	1.21	2.81	2.81	2.81	2,806.61	
	157.78	32.69	323.31	233.02	2,442.13	2,806.61	2,806.61		

2 The consolidated financials results of the Company include financials of three subsidiaries namely JHS Svendgaard Brands Limited (formerly known as JHS Svendgaard Dental Care Limited), JHS Svendgaard Mechanical and Warehouse Private Limited & JHS Svendgaard Retail Ventures Private Limited.

3 The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in the respective meetings held on 12th February, 2019. The same have been reviewed by the Statutory Auditors of the Company as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

4 The Company has invested an amount of Rs 650 lakhs in Equity shares of JHS Svendgaard Retail Ventures Private Limited on 13th April 2018. Due to this investment JHS Svendgaard Retail Ventures Private Limited has become subsidiary of JHS Svendgaard Laboratories Limited. The company holds 99.82 % of the total share capital of JHS Svendgaard Retail ventures Private Limited

5 The Company has further invested in its existing subsidiary, JHS Svendgaard Brands Limited amounting to Rs. 581 lakhs on 12th April 2018. Further JHS Svendgaard Brands Limited has also done preferential allotment to other shareholders. Accordingly the revised shareholding of JHS Svendgaard Laboratories Limited in JHS Svendgaard Brands Limited stands decreased from 95.12% on 31st March 2018 to 62.01% as on 31st December 2018.

6 The initial accounting for business combinations with respect to investment in JHS Svendgaard Retail Ventures Private Limited by JHS Svendgaard Laboratories Limited, and the acquisition of business for 'Panache' brand by JHS Svendgaard Brands Limited have been duly accounted so far, subject to further adjustments such as purchase price allocation analysis etc., and hence the group has accounted for these business combinations on provisional basis in accordance with Ind AS 103 'Business Combinations'.

7 Paid up equity share capital includes 1,63,60,000 equity shares allotted pursuant to conversion of share warrants. These shares are under process for listing.

8 The segment results & capital employed are currently not realistically ascertainable as the Company has invested in JHS Svendgaard Retail Ventures Private Limited during the year. Pending the assessment of business performance by Chief operating decision maker (CODM) in light of recent developments in the business acquisition the necessary disclosure as required by Ind AS-108 has not been made.

9 Ind As 115 'Revenue from contracts with customers' has been made applicable w.e.f 1st April 2018. The group has assessed that there is no significant impact of Ind As 115 on these financial results.

10 Deferred tax includes MAT credit entitlement of Rs 50.16 lakhs for the current quarter and Rs 70.05 lakhs for nine months period ended 31st December 2018.

11 Revenue from operations for the current quarter are not comparable with previous periods, since sales for the current quarter are net of Goods and Services Tax (GST), whereas excise duty formed part of the other expenses in the corresponding quarter.

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months	Nine Months	Year Ended 31st March 2018
	31st Dec 2018	30th Sep 2018	31st Dec 2017	Ended 31st Dec 2018	Ended 31st Dec 2017	
Sales/Revenue from operations (as reported)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Less: Excise duty on sales	3,943.10	2,978.22	4,381.37	8,924.51	10,484.31	14,264.19
Sales/Income from operations (net of excise duty)				8,924.51	10,249.28	235.03
		2,978.22	4,381.37			14,029.16

12 There has been a major movement in exchange fluctuation in the current quarter as compared to the already recognised gain till september quarter as a result of which the other income figure is negative in the current quarter.

13 The Statutory Auditors had qualified their audit report on the financial statements of the Company for the year ended 31st March 2018 in respect of revenue recognition. However this qualification has no impact on current reportable period.

14 Figures for the previous quarters/years have been regrouped and reclassified to conform with current quarter/year presentation, where ever applicable.

Place : New Delhi
 Date : 12 February, 2019



By Order of the Board
 Nikhil Nanda
 Managing Director
 DIN : 00051501



JHS Svendgaard Laboratories Limited announces Consolidated Q3 FY18-19 results Revenues were at Rs. 39.05 crore

New Delhi, February 12, 2019: JHS Svendgaard Laboratories Ltd. (JHS) one of India's leading Oral-care manufacturing companies reported its financial results for the third quarter ended 31st December, 2018

Q3FY19 Highlights:

- Total revenues were at Rs 39.05 crore
- EBIDTA was at Rs 3.76 crore
- EBITDA Margin stood at 9.63%
- Net profit was at Rs 0.84 crore

9M FY19 Highlights:

- Total revenues were at Rs 92.15 crore
- EBIDTA was at Rs 2.73 crore
- EBITDA Margin stood at 2.96%
- Net profit was at Rs -0.55 crore

Operational Highlights

- The revenues for the quarter are 30% up for the third quarter, when compared to previous quarter. This was because of correcting supply chain issues with one of its clients under contract manufacturing business. Current quarter revenues also includes export revenues which has resulted in better capacity utilization
- JHS through its subsidiary JHS Svendgaard Retail Ventures Pvt. Ltd. has opened two more retail outlets at Swami Vivekanand Airport, Raipur, Chhattisgarh and Chandigarh International Airport Limited, Mohali besides New Delhi Terminal 2 for Patanjali. The company is well geared up to increase its presence across all major Airports in India.
- JHS through its another subsidiary JHS Svendgaard Brands Ltd. has further extended its presence into the modern trade space under its proprietary brand “aquawhite” focusing on Kids range by making product available at Big Bazaar, Relay stores at airport, Easy Day, 37 Krishna Marche.
- JHS Svendgaard Brands Ltd. has signed one more kid's favorite character 'Angry Birds' in its character portfolio for kid's oral-care range
- JHS Svendgaard Brands Ltd. has signed celebrity actor Tiger Shroff as brand ambassador for “aquawhite”

Final
check



Management Comments:

Commenting on the results, **Mr. Nikhil Nanda, Managing Director**, said, “We are very happy to deliver revenue growth during the quarter on a sequential quarter basis. Our branded product under “aquawhite” is focusing on distribution channels to increase contribution from this segment is expected to grow in the coming quarters.”

He further added “I believe that the demand for oral care products in India will continue to remain robust considering the low penetration and shortening the time of replacing the brush with changing demographics of economy. We are focused to further increase our market share and expand our customer base in Northern and Western markets by streamlining our distribution.”

About JHS Svendgaard Laboratories Limited (JHS):

JHS is a 14 year old company listed on the National Stock Exchange (“**NSE – JHS**”) and Bombay Stock Exchange (“**BSE – 532771**”) of India.

JHS with an experience of around 3 decades into manufacturing of complete Oral-Care range and is catering to an extensive range of Oral Care products for some of the largest Brands into the Oral Care category.

Apart from the private label manufacturing business, the company under its subsidiary JHS Svendgaard Brands Ltd. possesses proprietary brand “**aquawhite**” and is the largest licensor of the most prominent kids characters in India such as **Chhota Bheem, Angry Birds, Pokemon, SpongeBob SquarePants, Shimmer & Shine, Shiva, Jungle Books, PAW Patrol** and many more to manufacture Oral Care range for kids in India.

The company has been signed up by Patanjali Ayurved Ltd. as the exclusive partner for setting up, maintaining and operating retail stores exclusively at Airports.

Forward-Looking Statements:- This report contains forward –looking statements, which may be identified by their use of words like ‘plans’, ‘expects’, ‘will’, ‘anticipates’, ‘believes’, ‘intends’, ‘projects’, ‘estimates’ or other words of similar meaning. All statements that address expectations or projections about the future, including but not limited to statements about the company’s strategy for growth, market position, expenditures, and financial results, are forward –looking statements. Forward-looking statements are based on certain assumptions and expectations of future events. The company cannot guarantee that these assumptions and expectations are accurate or will be realized. The company’s actual results, performance or achievements could thus differ materially from those projected in any such forward – looking statements. The company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events.

For more details about JHS Svendgaard Laboratories Limited, please visit www.svendgaard.com

Key Contacts:

Corp Communications: Ms. Neetal Narang President – Corporate Affairs neetal@svendgaard.com 011-29949675	Investor Relations: Mr. Ashish Goel Group CFO ashish@svendgaard.com 011-29949675
---	--

Handwritten signature and date: 12/07/19